PMID- 22647307
OWN - NLM
STAT- MEDLINE
DCOM- 20150611
LR  - 20220317
IS  - 1662-4033 (Electronic)
IS  - 1662-4025 (Linking)
VI  - 5
IP  - 2
DP  - 2012
TI  - The impact of type 2 diabetes on circulating adipokines in patients with 
      metabolic syndrome.
PG  - 270-6
LID - 10.1159/000338729 [doi]
AB  - AIM: The aim of the study was to investigate, whether type 2 diabetes 
      independently influences adipokines and inflammatory markers in patients with 
      metabolic syndrome. METHODS: 36 patients with metabolic syndrome without type 2 
      diabetes and 39 patients with metabolic syndrome with type 2 diabetes, carefully 
      matched for age, sex, and BMI, were investigated. Primary outcome measures were 
      circulating adipokines and inflammatory markers (adiponectin, leptin, visfatin, 
      vaspin, resistin, TNF-alpha, IL-6, monocyte chemoattractant protein-1 (MCP-1), 
      retinol binding protein 4 (RBP-4), growth differentiation factor-15 (GDF-15)). In 
      addition, we determined parameters of glucose and lipid metabolism. RESULTS: 
      Patients with metabolic syndrome and type 2 diabetes had significantly lower 
      levels of plasma total cholesterol, low-density lipoprotein cholesterol and 
      triglycerides (p < 0.05). They displayed higher GDF-15 concentrations (1,113 +/- 
      135 vs. 656 +/- 63 pg/ml, p = 0.005) and lower visfatin concentrations (3.7 +/- 0.3 
      vs. 4.8 +/- 0.2 ng/ml, p = 0.009). There were no differences in other adipokines 
      and inflammatory markers between both groups. CONCLUSIONS: In patients with 
      metabolic syndrome, type 2 diabetes leads to decreased visfatin and increased 
      GDF-15 serum levels when compared to carefully matched non-diabetic subjects. 
      Whether the increase in GDF-15 is an indicator or a causal factor for the 
      increased cardiovascular risk in diabetic subjects remains to be investigated in 
      further studies.
CI  - Copyright (c) 2012 S. Karger GmbH, Freiburg.
FAU - Schindler, Karin
AU  - Schindler K
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine III, 
      Medical University Vienna, Vienna, Austria.
FAU - Vila, Greisa
AU  - Vila G
FAU - Hoppichler, Friedrich
AU  - Hoppichler F
FAU - Lechleitner, Monika
AU  - Lechleitner M
FAU - Luger, Anton
AU  - Luger A
FAU - Anderwald, Christian
AU  - Anderwald C
FAU - Hoefler, Jurgen
AU  - Hoefler J
FAU - Tomasec, Goran
AU  - Tomasec G
FAU - Kautzky-Willer, Alexandra
AU  - Kautzky-Willer A
FAU - Ludvik, Bernhard
AU  - Ludvik B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120421
PL  - Switzerland
TA  - Obes Facts
JT  - Obesity facts
JID - 101469429
RN  - 0 (Adipokines)
RN  - 0 (Growth Differentiation Factor 15)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipids)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
SB  - IM
MH  - Adipokines/*blood
MH  - Cardiovascular Diseases/blood/etiology
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood/complications
MH  - Female
MH  - Growth Differentiation Factor 15/*blood
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Lipids/blood
MH  - Male
MH  - Metabolic Syndrome/*blood/complications
MH  - Middle Aged
MH  - Nicotinamide Phosphoribosyltransferase/*blood
MH  - Risk Factors
EDAT- 2012/06/01 06:00
MHDA- 2015/06/13 06:00
CRDT- 2012/06/01 06:00
PHST- 2011/07/27 00:00 [received]
PHST- 2011/08/26 00:00 [accepted]
PHST- 2012/06/01 06:00 [entrez]
PHST- 2012/06/01 06:00 [pubmed]
PHST- 2015/06/13 06:00 [medline]
AID - 000338729 [pii]
AID - 10.1159/000338729 [doi]
PST - ppublish
SO  - Obes Facts. 2012;5(2):270-6. doi: 10.1159/000338729. Epub 2012 Apr 21.